Along with the above mentioned duties, I left my house every Monday and got home on Friday. Stayed in hotels every week and literally lived out of a suitcase. What did I get being a 50 something..... terminated.
-
Tue news: 23andMe CEO no longer open to takeover. mRNA vaccines may boost cancer immunotherapy. BMS beats $6.4B lawsuit. CVS Health layoffs and potential breakup. JNJ abandoning proposed 340b plan. See more on our front page
If the job is a joke and I won't leave - does that make me a joke too?
- Thread starter Anonymous
- Start date
-
- Tags
- None
Along with the above mentioned duties, I left my house every Monday and got home on Friday. Stayed in hotels every week and literally lived out of a suitcase. What did I get being a 50 something..... terminated.
QA employee here. Reps seem to be in a job with excessive accountability and very little control over their territory's sales performance. That alone tells me the job is a big mindf#@*k. You can make decent money if you play the game well and can keep your CTL off your ass. The job is much more of a game now than ever before and that's the hardest part of it. I assume successful reps must focus on their skills at playing the game well and that's wherein job satisfaction is derived. Opportunities for job satisfaction from providing meaningful value to the customer are extremely rare unless long-standing customer relationships in the territory still exist which also are extremely rare. Is this a fairly accurate assessment?
seriously? Thats really unusual for a rep to have to be away that amount of time, is your territory in Alaska or something?
I wouldn't claim to be respected by everyone all the time, but what I can say is that managers treat reps pretty well, they don't harass them like I hear about on CP, but they do try to help them be the best they can be and sometimes my counterparts get all pissed off about that. Thats their job, and most of them (MOST not all) really do try to be good managers. It takes a lot of stress to PIP someone or manage someone out, its not fun, its not easy, it takes its toll on the whole group - its a bf-pita to be blunt. I think most people just want to get up and do their work and not have everything be so freaking difficult. I don't think its the managers who have made things super difficult, I think the organization (pb&c legal, marketing, etc) has pushed a bunch of crap down that they don't have to implement, and since merck is so freaking silo'ed those who create the crap don't have to use the crap, so everyone including managers just start pushing the crap around like kids push pea's on their plate.
when you say your region is negative, what exactly does that mean? there is definitely alot of negativity out there, but if its just everyone grumbling because its easy to bitch, thats different than working in a really degrading shitty environment. I would be interested to hear.
You speak for yourself.
You do not know the actions of those you think you know either....
No you are not a joke, but you are taking it a bit too seriously. If you have your faith and health you have a lot. Yes this job is a total joke and yes all the patients in the waiting room are looking at you as the enemy. Docs dont wat to talk to you anymore. the most interesting thing about all the previous reps that post on here is how happy they are after they leave. There must be something to that you know, you should try it becuase life is too short to be miserable like you describe. Money aint everything. there are far more dignified ways to make a living than being a drug rep
You may be right but a little bit idealistic. When managers are being threatened by their directors about sales performance, it does not take long for them to figure ways, including PIPs, to "motivate" the reps and keep their jobs. May be it was not the original intention but slowly it became the norms at Merck. Obviously the whole corporate culture at Merck has taken a major shift over the last decade.
thanks for the thoughtful, intelligent and articulate posting...and yes, I did end up
leaving (even though I have no new job) and you are right that I am much happier being
away from the toxic company Merck...
FU MERCK!!
Yes,thoughtful, intelligent and articulate.....but only if you have 10-30 y/in and can cheer about getting a fat package and a retirement set in waiting.....
.....all others you are living a fantasy about money and totally stupid.......
The following article is a joke. Merck is lying to the press and to the reps if they are ac
tually allowing the title of this article to happen.
Drug Reps Soften Their Sales Pitches .
Article
Slideshow
Stock Quotes
Comments (5)
more in Health ».
By JONATHAN D. ROCKOFF
GREENSBORO, N.C.—One thing was noticeably absent from a recent visit that an Eli Lilly & Co. sales representative paid to a psychiatrist here: a sales pitch.
Michaelene Greenly provided free drug samples, a lunch of salad and iced tea, and a chance to order diagrams of how the brain works. What she didn't do: tout her drugs' benefits or ask the doctor to write more prescriptions. Nevertheless, Lilly's sales of the neuroscience drugs she promotes are rising.
View Slideshow
Travis Dove for The Wall Street Journal
Michaelene Greenly, a pharmaceutical sales representative for Eli Lilly, placed her samples on a shelf at Dr. Parish McKinney's psychiatary practice in Greensboro, N.C.
.
"We used to come in with our own agenda: What can I accomplish today? We've turned that all around. It's what the doctor talks about," Ms. Greenly said.
Her soft sell reflects a major shift in how more pharmaceutical companies target physicians, as the industry remakes its commercial model in response to changing economic and regulatory conditions. Traditionally, armies of sales reps have fanned out to "detail" doctors with aggressive, well-rehearsed sales pitches and pressure to boost prescriptions. Multiple sales reps from one company might call on the same physician. That strategy over the past 15 years helped propel the industry to $300 billion in yearly U.S. sales today.
But the approach has been in flux. Physicians, under pressure from health plans to curb costs, have less time for, and patience with, persistent sales pitches. The government has been cracking down on aggressive, illegal marketing of drugs for unapproved uses. And drug makers, unable to bring enough new products to market to fully offset patent losses, have been forced to tighten belts.
.
As a result, the industry has slashed 33,000 sales jobs in the U.S. from its peak five years ago, when 105,000 representatives flooded the zone. Most recently, AstraZeneca PLC said it would cut its U.S. sales staff by 24%, or 1,150 jobs. The industry spent $14.5 billion on marketing in the U.S. in 2010, down about 15% from five years ago, according to Cegedim Strategic Data.
Both to adjust to and allow for these changes, some 18 of the top 40 drug makers have reorganized their sales forces to reduce duplication, one industry consultant says. In the wake of costly settlements by other drug makers over illegal marketing practices, British drug giant GlaxoSmithKline PLC stopped evaluating salespeople based on the number of prescriptions written. Instead, companies are considering how well physicians rate their representatives.
Drug makers including GlaxoSmithKline PLC, Merck & Co. and Lilly are also asking their representatives to switch from making forceful, tightly scripted sales pitches to acting more like a resource supporting physicians' treatment. Companies hope to get a foot in the door by providing practical help, such as assistance educating patients about their diseases or navigating reimbursement.
"Increasing physician satisfaction, it turns out, is a much better way to promote a pharmaceutical agent than simply telling them to write more prescriptions or what the benefits" are, said David Ricks, president of Lilly's global business unit.
Shifting gears has proven thorny in some cases, said Chris Wright of ZS Associates, a marketing and sales consulting firm. Some longtime sales representatives, used to repeating a scripted message, aren't equipped to intuit and respond to what doctors want. Promotion of drugs is highly regulated, making it tricky to give salespeople lots of leeway in what they discuss with physicians.
Enlarge Image
Travis Dove for The Wall Street Journal
Ms. Greenly, seen with Dr. Andrew Farah in North Carolina, is responsible for selling Lilly's neuroscience drugs.
.
Also, salespeople still can't provide the one thing many doctors want above all: more time to see patients. "As pharmaceutical companies try to engage in a nicer, more pleasant way, they don't always get a positive reception because nothing is being done to solve the doctors' time problem," said Mr. Wright, who runs ZS Associates' global pharmaceuticals practice.
Physicians feel pressured to fit more patients—not sales reps—into their workdays to offset the cost-control efforts imposed by health plans. In addition, doctors feel they have lost some authority picking medicines, as health plans have learned to wield co-pays to steer use of certain drugs.
Sales representatives still pay 115 million visits to 340,000 doctors each year, and some companies and reps have kept up the old, aggressive tactics. Doctors still complain about receiving inappropriate pitches from particular firms, and many hold the pharmaceutical industry and its marketing practices in low esteem. Earlier this year, 23% of 680,000 doctors surveyed by market research firm SK&A said they refused to even see drug reps.
Eli Lilly decided to adopt its new approach after watching launches of new drugs like Strattera for attention deficit-hyperactivity disorder and the blood thinner Effient stumble, according to Mr. Ricks. One possible problem the company identified was a mismatch between what doctors expected based on sales pitches, and what the products delivered.
Now, the company's sales team draws marketing lessons from how Disney keeps families coming to its amusement parks. Lilly's most recent national sales meeting, held at Disney's business training institute in Florida in February, was devoted to customer service, not product training. Sales representatives watched how Animal Kingdom workers greeted families at the gate and answered questions around the attractions.
Surveys of doctors show that 85% are satisfied with Lilly, up from the 60% before the company changed ways, Mr. Ricks says. U.S. sales of antidepressant Cymbalta were $2.98 billion during the first nine months of 2011, more than $450 million higher than during the same period in 2010, according to Wolters Kluwer Pharma Solutions, a data firm. Strattera sales are on pace to surpass 2010's $575 million, and sales of Effient have also picked up, totaling $217 million through October, more than double 2010's tally.
Among those turned off generally by aggressive tactics in years past was psychiatrist Parish McKinney, who owns a practice in Greensboro, N.C. Some representatives took seats in her waiting room, while patients stood. She recalled some opening their laptops to review her prescription numbers, say she wasn't prescribing enough of their drugs and request she write the "next five" for their products.
Also, she said, Lilly representatives downplayed the weight gain that Dr. McKinney saw among some patients taking the company's blockbuster antipsychotic Zyprexa. The salespeople said the issue wasn't any worse than competing drugs, although Dr. McKinney experienced otherwise. They reminded her about Zyprexa's effectiveness.
"They were trying to press hard. They would not acknowledge it was a concern," Dr. McKinney said.
A company spokeswoman said Lilly always told doctors about the known risks of Zyprexa, and its original label listed weight gain as a possible side effect.
In 2007, Lilly added to Zyprexa's label a more specific warning about the potential for weight gain. Separately, Lilly agreed in 2009 to plead guilty to a misdemeanor violation of federal drug laws and pay $1.4 billion for promoting Zyprexa for treatment of dementia in elderly patients, even though the drug wasn't approved for that use.
When she began calling on Dr. McKinney two years ago, Lilly's Ms. Greenly spoke frankly about weight gain, Dr. McKinney recalled. Ms. Greenly provided data for predicting the increase and deciding whether to use another drug. Lilly made available a nutrition program to help patients manage weight gain—even if they were taking competitors' products.
"It felt more like they were starting to listen to our concerns—whether good or bad—about what we were experiencing in our office," Dr. McKinney said.
On a recent day visiting psychiatrists and nurse practitioners, Ms. Greenly, 46 years old, wore a conservative brown suit and a badge with her name and Lilly's. She is responsible for selling the company's neuroscience drugs in a broad swath of central North Carolina. The job combines her childhood dream of becoming a doctor with her college sales and marketing studies. She has worked for Lilly since 2001.
Under the drug maker's personality testing of employees, Ms. Greenly is a "red" for her outgoing, ambitious traits. Yet, she says she always chafed at the company's old, hard sells. She didn't like repeating messages like "Cymbalta is good for depression" over and over, and found that doctors tuned out such pitches.
Before the change in tactics, psychiatrist Carey Cottle Jr. says he was more likely to write prescriptions for a competing antidepressant like Pfizer Inc.'s Effexor over Cymbalta, because Lilly representatives had a "high-pressure, car sales-type approach, and it was just not appropriate." Fed up several years ago, Dr. Cottle called their Lilly manager and complained that the reps' visits were "wasting our time."
Now, Ms. Greenly's service has lifted the bias he had against prescribing Lilly medicines, Dr. Cottle says. When he had a patient who was breast-feeding, she supported his conclusion that it would be safer if the woman took the antipsychotic Risperdal instead of Lilly's Zyprexa because Risperdal had more safety data on that point.
While they ate salads and drank tea in his office, Dr. Cottle expressed concern that a severely depressed women who was finally improving on Zyprexa had gained 30 pounds. Ms. Greenly offered to inquire about enrolling the patient in Lilly's nutrition program.
She also showed him various illustrations of the brain, which he could pick from and Lilly would print for his use, explaining to patients how a drug would work. He said he'd been looking on the Web for just such diagrams. Lilly would print the pictures with Dr. Cottle's name, not the company's.
Ms. Greenly left a collection for Dr. Cottle to choose from. As she stood to walk out of the office, Dr. Cottle thanked her and asked, "When will I see you again?"
Write to Jonathan D. Rockoff at jonathan.rockoff@wsj.com
tually allowing the title of this article to happen.
Drug Reps Soften Their Sales Pitches .
Article
Slideshow
Stock Quotes
Comments (5)
more in Health ».
By JONATHAN D. ROCKOFF
GREENSBORO, N.C.—One thing was noticeably absent from a recent visit that an Eli Lilly & Co. sales representative paid to a psychiatrist here: a sales pitch.
Michaelene Greenly provided free drug samples, a lunch of salad and iced tea, and a chance to order diagrams of how the brain works. What she didn't do: tout her drugs' benefits or ask the doctor to write more prescriptions. Nevertheless, Lilly's sales of the neuroscience drugs she promotes are rising.
View Slideshow
Travis Dove for The Wall Street Journal
Michaelene Greenly, a pharmaceutical sales representative for Eli Lilly, placed her samples on a shelf at Dr. Parish McKinney's psychiatary practice in Greensboro, N.C.
.
"We used to come in with our own agenda: What can I accomplish today? We've turned that all around. It's what the doctor talks about," Ms. Greenly said.
Her soft sell reflects a major shift in how more pharmaceutical companies target physicians, as the industry remakes its commercial model in response to changing economic and regulatory conditions. Traditionally, armies of sales reps have fanned out to "detail" doctors with aggressive, well-rehearsed sales pitches and pressure to boost prescriptions. Multiple sales reps from one company might call on the same physician. That strategy over the past 15 years helped propel the industry to $300 billion in yearly U.S. sales today.
But the approach has been in flux. Physicians, under pressure from health plans to curb costs, have less time for, and patience with, persistent sales pitches. The government has been cracking down on aggressive, illegal marketing of drugs for unapproved uses. And drug makers, unable to bring enough new products to market to fully offset patent losses, have been forced to tighten belts.
.
As a result, the industry has slashed 33,000 sales jobs in the U.S. from its peak five years ago, when 105,000 representatives flooded the zone. Most recently, AstraZeneca PLC said it would cut its U.S. sales staff by 24%, or 1,150 jobs. The industry spent $14.5 billion on marketing in the U.S. in 2010, down about 15% from five years ago, according to Cegedim Strategic Data.
Both to adjust to and allow for these changes, some 18 of the top 40 drug makers have reorganized their sales forces to reduce duplication, one industry consultant says. In the wake of costly settlements by other drug makers over illegal marketing practices, British drug giant GlaxoSmithKline PLC stopped evaluating salespeople based on the number of prescriptions written. Instead, companies are considering how well physicians rate their representatives.
Drug makers including GlaxoSmithKline PLC, Merck & Co. and Lilly are also asking their representatives to switch from making forceful, tightly scripted sales pitches to acting more like a resource supporting physicians' treatment. Companies hope to get a foot in the door by providing practical help, such as assistance educating patients about their diseases or navigating reimbursement.
"Increasing physician satisfaction, it turns out, is a much better way to promote a pharmaceutical agent than simply telling them to write more prescriptions or what the benefits" are, said David Ricks, president of Lilly's global business unit.
Shifting gears has proven thorny in some cases, said Chris Wright of ZS Associates, a marketing and sales consulting firm. Some longtime sales representatives, used to repeating a scripted message, aren't equipped to intuit and respond to what doctors want. Promotion of drugs is highly regulated, making it tricky to give salespeople lots of leeway in what they discuss with physicians.
Enlarge Image
Travis Dove for The Wall Street Journal
Ms. Greenly, seen with Dr. Andrew Farah in North Carolina, is responsible for selling Lilly's neuroscience drugs.
.
Also, salespeople still can't provide the one thing many doctors want above all: more time to see patients. "As pharmaceutical companies try to engage in a nicer, more pleasant way, they don't always get a positive reception because nothing is being done to solve the doctors' time problem," said Mr. Wright, who runs ZS Associates' global pharmaceuticals practice.
Physicians feel pressured to fit more patients—not sales reps—into their workdays to offset the cost-control efforts imposed by health plans. In addition, doctors feel they have lost some authority picking medicines, as health plans have learned to wield co-pays to steer use of certain drugs.
Sales representatives still pay 115 million visits to 340,000 doctors each year, and some companies and reps have kept up the old, aggressive tactics. Doctors still complain about receiving inappropriate pitches from particular firms, and many hold the pharmaceutical industry and its marketing practices in low esteem. Earlier this year, 23% of 680,000 doctors surveyed by market research firm SK&A said they refused to even see drug reps.
Eli Lilly decided to adopt its new approach after watching launches of new drugs like Strattera for attention deficit-hyperactivity disorder and the blood thinner Effient stumble, according to Mr. Ricks. One possible problem the company identified was a mismatch between what doctors expected based on sales pitches, and what the products delivered.
Now, the company's sales team draws marketing lessons from how Disney keeps families coming to its amusement parks. Lilly's most recent national sales meeting, held at Disney's business training institute in Florida in February, was devoted to customer service, not product training. Sales representatives watched how Animal Kingdom workers greeted families at the gate and answered questions around the attractions.
Surveys of doctors show that 85% are satisfied with Lilly, up from the 60% before the company changed ways, Mr. Ricks says. U.S. sales of antidepressant Cymbalta were $2.98 billion during the first nine months of 2011, more than $450 million higher than during the same period in 2010, according to Wolters Kluwer Pharma Solutions, a data firm. Strattera sales are on pace to surpass 2010's $575 million, and sales of Effient have also picked up, totaling $217 million through October, more than double 2010's tally.
Among those turned off generally by aggressive tactics in years past was psychiatrist Parish McKinney, who owns a practice in Greensboro, N.C. Some representatives took seats in her waiting room, while patients stood. She recalled some opening their laptops to review her prescription numbers, say she wasn't prescribing enough of their drugs and request she write the "next five" for their products.
Also, she said, Lilly representatives downplayed the weight gain that Dr. McKinney saw among some patients taking the company's blockbuster antipsychotic Zyprexa. The salespeople said the issue wasn't any worse than competing drugs, although Dr. McKinney experienced otherwise. They reminded her about Zyprexa's effectiveness.
"They were trying to press hard. They would not acknowledge it was a concern," Dr. McKinney said.
A company spokeswoman said Lilly always told doctors about the known risks of Zyprexa, and its original label listed weight gain as a possible side effect.
In 2007, Lilly added to Zyprexa's label a more specific warning about the potential for weight gain. Separately, Lilly agreed in 2009 to plead guilty to a misdemeanor violation of federal drug laws and pay $1.4 billion for promoting Zyprexa for treatment of dementia in elderly patients, even though the drug wasn't approved for that use.
When she began calling on Dr. McKinney two years ago, Lilly's Ms. Greenly spoke frankly about weight gain, Dr. McKinney recalled. Ms. Greenly provided data for predicting the increase and deciding whether to use another drug. Lilly made available a nutrition program to help patients manage weight gain—even if they were taking competitors' products.
"It felt more like they were starting to listen to our concerns—whether good or bad—about what we were experiencing in our office," Dr. McKinney said.
On a recent day visiting psychiatrists and nurse practitioners, Ms. Greenly, 46 years old, wore a conservative brown suit and a badge with her name and Lilly's. She is responsible for selling the company's neuroscience drugs in a broad swath of central North Carolina. The job combines her childhood dream of becoming a doctor with her college sales and marketing studies. She has worked for Lilly since 2001.
Under the drug maker's personality testing of employees, Ms. Greenly is a "red" for her outgoing, ambitious traits. Yet, she says she always chafed at the company's old, hard sells. She didn't like repeating messages like "Cymbalta is good for depression" over and over, and found that doctors tuned out such pitches.
Before the change in tactics, psychiatrist Carey Cottle Jr. says he was more likely to write prescriptions for a competing antidepressant like Pfizer Inc.'s Effexor over Cymbalta, because Lilly representatives had a "high-pressure, car sales-type approach, and it was just not appropriate." Fed up several years ago, Dr. Cottle called their Lilly manager and complained that the reps' visits were "wasting our time."
Now, Ms. Greenly's service has lifted the bias he had against prescribing Lilly medicines, Dr. Cottle says. When he had a patient who was breast-feeding, she supported his conclusion that it would be safer if the woman took the antipsychotic Risperdal instead of Lilly's Zyprexa because Risperdal had more safety data on that point.
While they ate salads and drank tea in his office, Dr. Cottle expressed concern that a severely depressed women who was finally improving on Zyprexa had gained 30 pounds. Ms. Greenly offered to inquire about enrolling the patient in Lilly's nutrition program.
She also showed him various illustrations of the brain, which he could pick from and Lilly would print for his use, explaining to patients how a drug would work. He said he'd been looking on the Web for just such diagrams. Lilly would print the pictures with Dr. Cottle's name, not the company's.
Ms. Greenly left a collection for Dr. Cottle to choose from. As she stood to walk out of the office, Dr. Cottle thanked her and asked, "When will I see you again?"
Write to Jonathan D. Rockoff at jonathan.rockoff@wsj.com
LOL....looks like the competition is finally adopting what we've done since implementing the NCM several years ago. Like all of us old-timers said....it's nothing new, we've been selling with this soft approach for years. I'm just lucky to have surprised a few punkassed managers who wanted to see the hardcore closing details on field visits. That meant I had to spend a day or two prepping the offices I would call on with him or her. This became a bitch when I din't have enough time to prepare for one of her short-notice fv's. Nice to see the worm turning - long overdue.
LOL....looks like the competition is finally adopting what we've done since implementing the NCM several years ago. Like all of us old-timers said....it's nothing new, we've been selling with this soft approach for years. I'm just lucky to have surprised a few punkassed managers who wanted to see the hardcore closing details on field visits. That meant I had to spend a day or two prepping the offices I would call on with him or her. This became a bitch when I din't have enough time to prepare for one of her short-notice fv's. Nice to see the worm turning - long overdue.
don't you see the insanity of staying in a profession where you have to "prep" offices
to bring in a dumb manager that is only coming on the "visit" to justify his own compeltely worthless job??
I am glad I got out of that stupid circus...it was nice getting a steady paycheck for working essentitally part time...
I just felt like such a fraud, and at a certain point, could no longer take myself seriously...I knew then it was time to get out....
No your not a joke. We all need to do something for money to live our private lives so if it's not affecting you that much then just try to smile, take up a new hobby you always wanted to try and see what happens.Ok..we all know this job is totally ridiculous at this point...
Yet, it is really tough to leave it, given the steady paycheck and
15 X 15 work hours...
Sometimes I lose respect for myself that I am an older (50s) drug
rep doing this silly job, of catering and signature collection.
If the job is a joke does that make me a joke too?? I don't want to
be a joke...I used to be taken seriously as a person before the industry
went to hell...
chime in...(And don't be too mean please--I can take a few punches
but Merck has me beat up enough these days...(
Good advice but I found it extremely difficult not to identify myself with my silly-assed drug rep job. I don't know if it was just my problem or a guy thing but I suspect women find it much easier to accept an inane job for the perks it affords them. I couldn't do it because I always viewed it as representing 1/3 of my life and there was no way I wanted to give up that much of my life to do a meaningless and extremely unsatisfying job. I say that knowing that no job is perfect and a majority of people aren't crazy about their work, but I do believe a majority of people do take pride in at least something they do as a part of their employment. Pharma sales was that way in the beginning for me. When nothing about the job could diminish the growing contempt I had for pharma sales, I knew my time was up.
I think these feelings (almost always?) emerge when you've been in the industry a long time and start getting some age on you. I'm female, and I came to HATE (understatement) my job and the crazy masquerade that it became. I was 42 when I left, and had been miserable for about 2 1/2 - 3 years. I stuck it out for a while, thinking I was going through a phase, but it just kept getting worse. I completely understand everything you say. Actually, I think that some people can deal with it, b/c they see it as just a job and means to an end (the ones who say "just get your satisfaction outside of work"...) , but I was like you. seeing it more like "I spend a huge chunk of my life doing this, and it sucks beyond words, so it's not worth it to me anymore"). 2 schools of thought I guess.
I should have left the job as SOON as I started feeling brain-dead, which was a long while back! I did myself NO favors by sticking around!
For me, the money became absolutely not worth how shitty I felt every, single day.
It's hard to even explain the weirdness and insanity of pharma unless you've been in it.
well said!! I have always posted on CP that women are not nearly as bothered by being drug reps and being screwed over daily by the companies, because they are used to getting fu(ked on a daily basis...
For guys, it is an emasculating, ridiculous way to make a living, that takes a toll on ones soul...
So glad I got out...wish I hadn't wasted so much time at Schmerck...got sucked into the lazy lifestyle...
FU MERCK!!
so true...great post...I wish I had gotten out years ago too...I have hated it since about 1995 but my parent's depression-era mentality raised me to never quit a job...so I stuck it out in misery all these years...finally got out when my loathing for Merck became so extreme it was ruining my life...
People don't understand how sick, twisted and phony pharma sales unless they have done it themselves...it is truly a bizarre profession, with absolutely no comparison...
it will make you crazy for sure...
FU MERCK!!